
Sign up to save your podcasts
Or
Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.
4.6
300300 ratings
Our colleague Jason Mast joins us to discuss an emerging trend in biotech: Cash-rich startups are laying off employees and tweaking their strategies amid a tough market for venture capital. We also look ahead to the biggest biotech stories coming in 2024, including some major data readouts and a few pivotal FDA decisions.
Here's where you can subscribe to our biotech newsletter, The Readout.
1,642 Listeners
4,323 Listeners
111,539 Listeners
469 Listeners
117 Listeners
5,892 Listeners
2,935 Listeners
391 Listeners
60 Listeners
84 Listeners
31 Listeners
141 Listeners
9 Listeners
190 Listeners
42 Listeners